Document ID: chunk:federal_register_of_legislation:F2006L02853:body:0:p7
Version: federal_register_of_legislation:F2006L02853
Segment Type: other
Provision Reference: 
Character Range: 18291–21117

of its global R&D as a result of participation in the Program.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence to support their claims under this merit criterion.

PART 4 – ASSESSMENT OF PROPOSALS FOR CHANGES TO THE AGREED PORTFOLIO OF ACTIVITIES

    9. If a recipient has submitted a proposal to the Department for approval of changes to the agreed portfolio of activities, including the addition of new activities, the discontinuance of activities, or the substitution of new activities in the place of discontinued activities, the delegate of the Minister may request the Board to assess the proposal.
    10. If the Board receives a request under clause 9, it must assess the proposal as soon as is practicable and provide the assessment to a delegate of the Minister.
   11. In undertaking an assessment of a proposal to change the agreed portfolio of activities the Board will determine:

        (a) whether any new activities that are proposed to be added to the agreed portfolio of activities are eligible Australian pharmaceutical R&D activities;
       (b) the effect that the proposed changes would have had on the relative merit of the application under the merit criteria in clause 8 if the revised portfolio of activities had been admitted for assessment instead of the proposed portfolio of activities in the funding round in which the application was assessed by the Board.

PART 5 – TECHNICAL ASSESSMENTS
    12. A delegate of the Minister may request the Board to provide a technical assessment as to whether an applicant's three year history of pharmaceutical R&D activities comprises pharmaceutical R&D activities.
    13.  A delegate of the Minister may request the Board to provide a technical assessment of the progress reported by a recipient against the technical milestones for the agreed portfolio of activities.
   14. A delegate of the Minister may request the Board to provide a technical assessment as to whether a specific activity undertaken or proposed to be undertaken by an applicant or a recipient is an eligible Australian pharmaceutical R&D activity.

   15. If the Board receives a request under clause 12, clause 13 or clause 14, it must assess the proposal as soon as is practicable and provide the assessment to a delegate of the Minister.

PART 6 - EVALUATION OF THE PROGRAM
    16. The Board must, at the request of a delegate of the Minister, cooperate with any independent evaluation of the program, and provide comment on the operations of these Directions.

PART 7 – REVOCATION OF EARLIER DIRECTIONS

   17.  The Pharmaceuticals Partnerships Program Directions No 1 of 2003 and the Pharmaceuticals Partnerships Program Directions No 1 of 2004 are